Journal
PHARMACEUTICS
Volume 12, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics12020194
Keywords
CAR-T cells; immunotherapy; B-cell malignancies; CD19; BCMA
Categories
Funding
- Emmanuel van der Schueren fellowship from Kom op tegen Kanker (Stand up to Cancer, Belgium)
- public utility foundation MeToYou (Belgium)
- Senior Clinical Investigator of the Research Fund (FWO)-Flanders (Belgium)
Ask authors/readers for more resources
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
